Justice appeals judge's ruling on embryonic stem cell work; Emergent BioSolutions wins $28.7M contract;

 @FierceBiotech: Bayer, Kythera ink $373M dermatology deal. Article | Follow @FierceBiotech

 @JohnCFierce: Tracking this Genzyme/Sanofi story in the press is like watching tennis. A very slow game of tennis. | Follow @JohnCFierce

> The U.S. Justice Department has appealed a federal court judge's controversial decision to issue a preliminary injunction against federal support for embryonic stem cell work. The decision has roiled research efforts and triggered a decision at the NIH to freeze new grants. Story

> Emergent BioSolutions has inked a $28.7 million contract with the National Institute of Allergy and Infectious Diseases for advanced development of the company's third generation anthrax vaccine candidate. Emergent release

> Shares of Alimera Sciences jumped yesterday on the news that the FDA is giving its drug candidate Iluvien priority review status. Alimera licensed the therapy from pSivida. Report

> Belgium's ThromboGenics says that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion has met its primary endpoint. ThromboGenics release

> Two university spinoffs in Scotland have merged forces. ImmunoSolv is joining with Grampian BioConsultants to pursue "a new biology of cell death." Report

> The FDA has approved a new version of Allergan's Lumigan for open angle glaucoma or ocular hypertension. Story

And Finally... New research suggests that people who like to blame their obesity on genetics are using a lame excuse. That weight can still come off with exercise and the right diet. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.